Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024
UK gene and cell therapy group Oxford Biomedica and US genetic medicines company Homology Medicines have agreed to establish a high-performing, full scope adeno-associated virus (AAV) manufacturing and innovation business in the USA. 28 January 2022
Replacing its retiring co-founder and chief executive Onno van de Stolpe, Belgium-based biotech Galapagos today announced that industry veteran Paul Stoffels will join the company as CEO effective April 1. 27 January 2022
Once touted as a potential successor to Merck & Co’s former boss Kenneth Frazier, Frank Clyburn is to leave his post as the company’s executive vice president and president, Human Health, to take up a role elsewhere. 21 January 2022
Austrian drug developer Marinomed Biotech today announced the appointment of Dr Cornelia Kutzer as chief business officer (CBO) of the company. 21 January 2022
New biotech company Altos Labs has launched today with the aim of unraveling the deep biology of cellular rejuvenation programming, with $3 billion fully committed from renowned company builders and investors. 19 January 2022
Polish biotech Ryvu Therapeutics has announced the appointment of Dr Hendrik Nogai to the role of chief medical officer effective February 1, 2022. 17 January 2022
German life sciences company Merck KGaA today announced new appointments in global R&D and strategy leadership for the Healthcare business sector. 13 January 2022
California-based insitro, a machine learning-driven drug discovery and development company, has announced the expansion of its leadership team. 12 January 2022
US clinical stage cell and gene therapy company Castle Creek Biosciences says it has acquired Novavita Thera, a pre-clinical gene therapy company focused on rare liver and metabolic diseases. 11 January 2022
Aiming to expand its rare diseases gene therapy portfolio, USA-based Kriya Therapeutics revealed on Friday it has acquired Warden Bio, a company developing novel AAV-mediated gene therapies for glycogen storage disorders (GSDs). 8 January 2022
Eikon Therapeutics, a pioneer in the application of live-cell super-resolution microscopy to drug discovery, has closed a $517.8 million Series B financing. 7 January 2022
US precision cancer therapy specialist Blueprint Medicines has appointed Kate Haviland to succeed Jeff Albers as chief executive (CEO), effective April 4, 2022. 6 January 2022
Effective January 3, German drugmaker STADA Arzneimittel is strengthening its biosimilars capabilities with the appointment of Erin Federman as global commercial head, Biosimilars and vice president. 5 January 2022
Anders Ullman, currently a member of the board of directors at Swedish Orphan Biovitrum, also known as Sobi, will become head of R&D and chief medical officer and replace Dr Ravi Rao. 13 December 2021
Privately-held Danish medical dermatology specialist LEO Pharma today said that its president and chief executive of two years, Catherine Mazzacco, has resigned from the position and will be leaving the company as of today. 30 November 2021
French AI-driven drug combo specialist Pharnext has announced the appointment of Dr Burkhard Blank as chief medical officer (CMO) and Head of Research & Development effective January 1, 2022. 23 November 2021
US biotech Biogen surprised industry watchers, with the announcement that Alfred (Al) Sandrock Jr, head of research and development, will retire from the company effective December 31, 2021. 17 November 2021
The Sustainable Markets Initiative (SMI), a network of global CEOs and private sector corporations targeting planet-friendly growth, has created a new task force focused on the healthcare sector. 4 November 2021
Swiss rare diseases specialist Santhera Pharmaceuticals today said it has appointed Stephanie Brown as president North America and a member of its executive management team, effective December 1. 4 November 2021